Skip to main content
. 2021 Mar 16;41(5):459–468. doi: 10.1007/s40261-021-01023-8

Fig. 3.

Fig. 3

Cost-effectiveness acceptability curve according to Monte Carlo simulations with 1000 iterations. Populations included are a CAD or PAD, b PAD, c CAD, d CAD and PAD, e CAD with CKD, and f CAD with HF. CAD coronary artery disease, PAD peripheral artery disease, CKD chronic kidney disease, HF heart failure, RIV rivaroxaban, ASA aspirin, ICER incremental cost-effectiveness ratio

HHS Vulnerability Disclosure